GMP: FDA - New draft guidances for Biosimilars

On 9 February the US Food and Drug Administration published three draft guidance documents on the development of biosimilar products. The intention of these documents is to meet the demands of the requirements of Patient Protection and Affordable Care Act.

kapitał ludzki

fundusz społeczny

Narodowe Centrum Badań i Rozwoju

innowacyjna gospodarka

rozwój regionalny